A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

NCT02643082 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: GFF MDI (PT003) 14.4/9.6μg
DRUG: Placebo MDI

Sponsor

Pearl Therapeutics, Inc.